ACADIA Pharmaceuticals Inc. Share Price & Technical Analysis
ACAD · $21.20 (+0.47%)
Healthcare / Biotechnology
$21.20
+0.47%
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog o…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-5% return in May, 16% avg return in past 3 year May month.
-21% return in 2026, 31% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -6% | -3% | -8% | 1% | -5% | – | – | – | – | – | – | – | -21% |
| 25 | 1% | 7% | -15% | -12% | 48% | 0% | 10% | 10% | -18% | 7% | 11% | 8% | 56% |
| 24 | -17% | -11% | -21% | -10% | -10% | 7% | 17% | -13% | -7% | -5% | 11% | 13% | -46% |
| 23 | 15% | 9% | -10% | 14% | 11% | 4% | 23% | -8% | -24% | 9% | -2% | 40% | 82% |
| 22 | -3% | 11% | 0% | -24% | -12% | -13% | 4% | 12% | 0% | -4% | -3% | 2% | -29% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.71B
P/E ratio
9.81
52W high
$28.35
52W low
$19.69
Volume
1,06,381
Beta
0.86
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is ACADIA Pharmaceuticals Inc. share price today?
- ACADIA Pharmaceuticals Inc. (ACAD) last traded around $21.20 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ACAD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ACAD. Download the app for real-time alerts.
- How can I analyze ACADIA Pharmaceuticals Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.